Sagimet Biosciences (SGMT) Current Assets (2022 - 2026)

Sagimet Biosciences' Current Assets history runs 5 years deep, the most recent figure standing at $107.7 million for Q1 2026.

• In Q1 2026, Current Assets fell 26.26% year-over-year to $107.7 million; the TTM figure through Mar 2026 stood at $107.7 million (down 26.26% YoY), while the FY2025 annual figure was $116.4 million, down 23.81% from the prior year.
• Current Assets was $107.7 million for Q1 2026 at Sagimet Biosciences, down from $116.4 million in the prior quarter.
• In the past five years, Current Assets ranged from a high of $194.5 million in Q1 2024 to a low of $21.4 million in Q2 2023.
• Historically, Current Assets has averaged $118.6 million across 5 years, with a median of $119.5 million in 2025.
• The sharpest annual moves came in 2024 and 2026: Current Assets jumped 680.89% in 2024, then retreated 26.26% in 2026.
• A 5-year view of Current Assets shows it stood at $32.8 million in 2022, then soared by 194.72% to $96.6 million in 2023, then surged by 58.08% to $152.8 million in 2024, then fell by 23.81% to $116.4 million in 2025, then declined by 7.46% to $107.7 million in 2026.
• The last three Current Assets figures came in at $107.7 million (Q1 2026), $116.4 million (Q4 2025), and $119.5 million (Q3 2025), per Business Quant data.